Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The scheme is fully digitized and covers approximately 45% of India's population
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Subscribe To Our Newsletter & Stay Updated
